HMOs constitute a significant component of mother’s milk, and offer short and long-term benefits to infants from birth onwards.
The tie up aims to enable the functional and immunological benefits of HMOs to become available to infants being fed with infant formulas.
In addition to the infant formulas, Jennewein intends to focus on adult nutrition.
Jennewein managing director and cofounder Stefan Jennewein said complex oligosaccharides in general and HMOs in particular show an enormous potential for use in human nutrition.
"The cooperation between Pfizer Nutrition and Jennewein Biotechnologie will accelerate the developments in this field by bringing together specific complementary competencies," Jennewein said.